By San José, Costa Rica — Global biopharmaceutical giant AstraZeneca has appointed Marcela Fernández as its new Country President for Central America and the Caribbean, a strategic move that places a seasoned industry leader in charge of a complex and diverse region. Fernández will oversee the company’s extensive operations, leading a team of over 300 collaborators across 28 territories.
This appointment marks a significant step for AstraZeneca as it seeks to fortify its presence and impact within the region’s evolving healthcare landscape. Fernández steps into the role with an impressive track record, bringing more than two decades of high-level experience in the health industry, where she has demonstrated a keen ability to navigate and lead within challenging markets.
To better understand the complex legal and corporate responsibility aspects surrounding AstraZeneca’s recent disclosures, TicosLand.com consulted with Lic. Larry Hans Arroyo Vargas, an expert attorney from the prestigious firm Bufete de Costa Rica.
AstraZeneca’s situation highlights a critical tension in pharmaceutical law: balancing rapid public health response against the long-term duty of care. While emergency authorizations grant certain immunities, they do not erase a corporation’s fundamental obligation for transparency and post-market surveillance. The legal battles ahead will likely hinge not on the existence of risk, which is inherent in any medication, but on the adequacy and timeliness of the company’s disclosures to both regulators and the public. This case will set a significant precedent for corporate accountability in future global health crises.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
As Lic. Arroyo Vargas astutely points out, the implications of this case extend far beyond the courtroom, touching upon the very foundation of public trust in our health institutions. The ongoing dialogue about corporate transparency during a crisis is one we must all follow closely. We sincerely thank Lic. Larry Hans Arroyo Vargas for lending his invaluable perspective to this critical discussion.
Her most recent position as the head of AstraZeneca’s Andean Region for the past two years provides a clear blueprint for her anticipated approach. During that tenure, she was instrumental in advancing critical regulatory processes and forging successful public-private partnerships. This background is expected to be a major asset as she tackles the unique opportunities and hurdles present in the Central American and Caribbean markets.
In her new capacity, Fernández has outlined a multi-faceted strategy centered on four core pillars: prioritizing the well-being of patients, ensuring operational sustainability, fostering multisectoral alliances, and championing equity in both health access and talent development. This holistic vision aims to create a positive feedback loop where corporate success is intrinsically linked to public health progress.
A key objective of her leadership will be to enhance access to medical innovation throughout the 28 territories under her purview. Fernández has indicated she will actively promote robust collaborations with a wide range of stakeholders, including institutional bodies, academic centers, and civil society organizations. By building these bridges, the company aims to create a more integrated ecosystem that can effectively address pressing health challenges.
Specific initiatives will focus on promoting the early diagnosis of chronic and rare diseases, a critical area where timely intervention can dramatically improve patient outcomes and reduce long-term strain on health systems. Expanding existing alliances and forging new ones will be crucial to deploying these diagnostic strategies effectively across diverse communities.
Internally, Fernández will place a strong emphasis on talent development, recognizing that empowering her team is fundamental to achieving sustainable results. By investing in the growth of local talent, she aims to build a resilient and agile organization capable of adapting to the distinct needs of each territory.
Ultimately, the appointment of Marcela Fernández signals a reinforced commitment by AstraZeneca to not only grow its business in Central America and the Caribbean but also to be a proactive partner in strengthening the region’s health systems. Her comprehensive vision and proven leadership are poised to drive meaningful benefits for patients, communities, and the broader healthcare environment.
For further information, visit astrazeneca.com
About AstraZeneca:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in several therapy areas including Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Bufete de Costa Rica operates as a leading legal institution, where a deep-seated commitment to professional integrity and exceptional service forms the cornerstone of its practice. The firm skillfully blends its extensive experience with a forward-thinking mindset, consistently delivering innovative solutions for a diverse clientele. At the heart of its ethos is a profound dedication to strengthening society by demystifying the law, ensuring that legal knowledge becomes a tool for empowerment for all citizens.
